Five Established Anticancer Agents: Clinical Evidence, Indications, and Global Pricing Insights

By:DengYue International Business Division

As a Hong Kong–based pharmaceutical export enterprise, DengYuemed has long focused on the global supply, clinical positioning, and market data analysis of oncology drugs. By integrating real-world clinical evidence with international pricing trends, we aim to provide healthcare professionals and patients with a clearer understanding of established anticancer therapies that continue to play an essential role in modern oncology.

This article reviews five well-established anticancer agents—Lobaplatin, Amsacrine, Procarbazine, Streptozocin, and Mitoxantrone—from three perspectives: approved indications, depth of clinical evidence, and global price comparison across China, Europe, and the United States.

Lobaplatin - Third-generation platinum-based antineoplastic agents

Indications

Lobaplatin is a third-generation platinum-based antineoplastic agent developed in China. It has been approved in China for the treatment of:

● Small cell lung cancer (SCLC)

● Metastatic or inoperable breast cancer

● Certain hematologic malignancies, including chronic myelogenous leukemia (CML)

Clinical Evidence and Rationale

Lobaplatin represents one of the most important indigenously developed platinum agents in China. Its clinical value is supported by multiple multicenter Phase II–III studies and extensive real-world use:

● Clinical trials in solid tumors such as cervical cancer, breast cancer, and lung cancer demonstrated overall response rates (ORR) and disease control rates (DCR) comparable to cisplatin or carboplatin–based regimens.

● Notably, Lobaplatin has shown antitumor activity in certain cisplatin-resistant tumor models, highlighting its role as an alternative platinum agent.

● Safety analyses consistently show lower nephrotoxicity and gastrointestinal toxicity compared with cisplatin, with thrombocytopenia identified as the primary dose-limiting toxicity—predictable and clinically manageable.

Clinical Positioning

Lobaplatin is widely regarded in China as a valuable substitute for traditional platinum agents, particularly in patients with renal impairment or poor tolerance to cisplatin.

Amsacrine - DNA topoisomerase II inhibitor

Indications

Amsacrine (m-AMSA) is a DNA topoisomerase II inhibitor historically used in the treatment of:

● Acute myeloid leukemia (AML), especially relapsed or refractory cases

● Selected lymphoid malignancies

Clinical Evidence and Rationale

Amsacrine holds a clear position in the evolution of leukemia therapy:

● Multiple clinical studies demonstrated that Amsacrine-containing regimens achieved complete remission (CR) in a subset of patients with refractory or relapsed AML.

● It has historically served as an alternative to anthracycline-based therapy, particularly in patients with prior treatment failure.

● Its toxicity profile—primarily bone marrow suppression and gastrointestinal reactions—is well characterized, allowing use under strict clinical monitoring.

Clinical Positioning

While no longer a frontline therapy, Amsacrine remains a clinically meaningful option in selected hematologic malignancies, supported by decades of treatment experience.

Procarbazine - Alkylating antineoplastic agents

Indications

Procarbazine is an alkylating agent most commonly used in:

● Hodgkin lymphoma

● Certain primary brain tumors

Clinical Evidence and Rationale

Among the five drugs discussed, Procarbazine has one of the strongest and longest clinical evidence bases:

● As a core component of classical combination regimens such as MOPP and COPP, Procarbazine contributed to high complete remission rates and long-term survival benefits in Hodgkin lymphoma.

● Long-term follow-up data demonstrated durable disease-free survival (DFS) and overall survival (OS), establishing its role in curative-intent therapy.

● Its efficacy and safety profile has been extensively documented in clinical guidelines and oncology textbooks worldwide.

Clinical Positioning

Procarbazine is widely considered a textbook-level cornerstone drug in the history of lymphoma treatment.

Streptozocin - Antitumour antibiotics

Indications

Streptozocin is a nitrosourea-derived antitumor antibiotic primarily indicated for:

● Metastatic pancreatic neuroendocrine tumors (pNETs), including islet cell carcinoma

Clinical Evidence and Rationale

Although its indications are narrow, Streptozocin’s clinical value is well established:

● Clinical studies have shown that Streptozocin-based regimens can reduce tumor burden and improve symptom control in patients with pancreatic neuroendocrine tumors.

● It is recognized in Western oncology guidelines as a standard treatment option for advanced pNETs.

● Its main risks—particularly renal toxicity and myelosuppression—are well understood and manageable with proper monitoring.

Clinical Positioning

Streptozocin is a highly indication-specific agent with no easy therapeutic substitute in its niche.

Mitoxantrone - Anthraquinone antineoplastic agents

Indications

Mitoxantrone is an anthracenedione antineoplastic agent used in:

● Acute myeloid leukemia (AML)

● Breast cancer and other solid tumors

Clinical Evidence and Rationale

Mitoxantrone has accumulated extensive clinical evidence across multiple tumor types:

● In AML, Mitoxantrone-based induction regimens have demonstrated reliable complete remission rates, particularly in combination chemotherapy.

● In breast cancer, studies show comparable efficacy to traditional anthracyclines, with a lower incidence of cardiotoxicity, making it suitable for selected patient populations.

● Its mechanism—DNA intercalation and topoisomerase II inhibition—is well characterized.

Clinical Positioning

Mitoxantrone is widely regarded as a balanced alternative to anthracyclines, combining efficacy with improved cardiac safety.

Global Price Comparison: China vs. Europe and the United States

From a global market perspective, these five agents belong to the category of established cytotoxic therapies, whose pricing differs significantly by region.

● United States & Europe

○ Monthly treatment costs typically range from USD 400 to USD 2,000, depending on dosage, formulation, and hospital procurement agreements.

○ Drugs with limited indications, such as Streptozocin, often carry higher unit prices due to restricted supply.

● China

○ Due to local manufacturing, centralized procurement policies, and Medicare negotiations, prices for traditional chemotherapy agents are substantially lower.

○ In many cases, treatment costs are 30–70% lower than in Western markets, enhancing affordability and access.

These differences underscore China’s growing importance as a cost-competitive supplier of high-quality oncology drugs to the global market.

Conclusion: The Growing Role of Chinese Oncology Drugs in Global Markets

Together, these five agents represent decades of validated clinical practice, supported by randomized trials, long-term follow-up data, and real-world use. While oncology continues to advance toward precision medicine, established chemotherapeutic agents remain indispensable, particularly in hematologic malignancies and selected solid tumors.

From our perspective at DengYueMed, we are witnessing a clear trend:

Chinese oncology drugs—supported by mature clinical evidence, reliable manufacturing, and competitive pricing—are gaining increasing recognition in international markets. As global demand for accessible cancer treatment continues to grow, China’s role in the international oncology supply chain is set to expand further.